Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SEL-212
- Development stage
- Phase 3
- Lead developer
- Sobi
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
SEL-212 is a combination therapy designed for the treatment of chronic refractory gout. It consists of two components: pegsiticase (SEL-037), a pegylated urate oxidase enzyme that converts uric acid into the more soluble allantoin, and SEL-110 (ImmTOR), a proprietary nanoparticle containing rapamycin. The ImmTOR component is designed to induce immune tolerance to the pegsiticase enzyme, thereby preventing the formation of anti-drug antibodies (ADAs) that typically limit the efficacy and safety of uricase-based therapies. By mitigating immunogenicity, SEL-212 aims to provide sustained reduction of serum uric acid levels and dissolution of urate deposits (tophi) in patients who have failed conventional therapy. The drug is administered as a monthly intravenous infusion.
- Brand names
- SEL-212SEL212SEL 212
- Other names
- pegsiticase + rapamycinpegsiticase + ImmTOR
02
Targets
FKBP1AMechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on SEL-212.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SEL-212.